StockData
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. (VKTX) shareholders

VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/30
$26.88+0.08 (+0.30%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
59.4%
76M of 128M shares
Institutional holders
434
75 new, 50 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
1 buys · 16 sales
Net sold $18.17M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
FMR LLC
Joint filing with Abigail P. Johnson (7.70%)
9,539,0677.70%13G (passive) amendmentSep 30, 2026
Vanguard Capital Management5,877,2635.08%13G (passive)Mar 31, 2026
Abigail P. Johnson
Joint filing with FMR LLC (5.10%)
5,772,0515.10%13G (passive) amendmentSep 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of VKTXValueChange% of portfolio
FMR LLC6,335,7564.97%$247.16M+311,0030.01%
BlackRock, Inc.6,189,6494.85%$241.46M−690,6410.00%
State Street Corp5,606,3944.40%$218.71M+1,210,8370.01%
Vanguard Capital Management LLC5,053,6633.96%$197.14M+41,1610.00%
Vanguard Portfolio Management LLC4,484,2633.52%$174.93M+19,9650.01%
Two Sigma Investments, LP3,937,4143.09%$153.60M−494,7280.11%
Morgan Stanley3,486,0402.73%$135.99M+472,1120.01%
Ameriprise Financial Inc2,156,0831.69%$84.11M+477,3380.02%
Geode Capital Management, LLC2,097,9811.65%$81.87M+15,9140.00%
American Century Companies Inc1,816,0501.42%$70.84M−262,5270.03%
D. E. Shaw & Co., Inc.1,605,9941.26%$62.65M−70,7190.03%
Bnp Paribas Arbitrage, Snc981,7000.77%$38.30M+441,2010.01%
Citadel Advisors LLC951,5150.75%$37.12M−310,7060.00%
Goldman Sachs Group Inc942,8410.74%$36.78M−17,7290.00%
UBS Group AG936,0550.73%$36.52M−411,4170.00%
JPMorgan Chase & Co915,1850.72%$36.39M+429,4820.00%
Jane Street Group, LLC899,5580.71%$35.09M+150,6090.00%
Susquehanna International Group, Llp816,3670.64%$31.85M+110,5580.00%
Raymond James Financial Inc794,6600.62%$31.00M−1,280,7430.01%
Vanguard Fiduciary Trust Co732,0470.57%$28.56M+21,6350.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202643476M59.4%75 / 144131 / 509M7M
Q1 202641473M57.5%67 / 155118 / 7121M10M
Q4 202542672M56.5%112 / 115134 / 4413M14M
Q3 202537074M57.9%51 / 142108 / 6913M16M
Q2 202539177M60.3%82 / 149109 / 5912M13M
Q1 202537278M61.3%66 / 16199 / 9912M15M
Q4 202440882M64.3%82 / 147127 / 8810M13M
Q3 202442286M67.5%95 / 178101 / 5717M8M
Q2 202438783M64.9%91 / 165102 / 7216M17M
Q1 202437383M65.5%202 / 7886 / 2627M23M
Q4 202319779M61.6%48 / 6154 / 3012M11M
Q3 202317977M60.7%31 / 6349 / 4312M9M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

269 funds held VKTX in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of VKTXValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF3,587,9982.81%$139.97M1.30%Jun 30, 2026
Vanguard Total Stock Market Index Fund3,500,1752.74%$136.54M0.01%Jun 30, 2026
Vanguard Small-Cap Index Fund2,528,2351.98%$98.63M0.05%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund1,458,4611.14%$56.89M0.12%Jun 30, 2026
Vanguard Extended Market Index Fund1,333,1781.05%$52.01M0.05%Jun 30, 2026
Heritage Fund1,331,5741.04%$42.26M0.80%Jul 31, 2026
Fidelity Advisor Growth Opportunities Fund1,062,1780.83%$34.78M0.10%May 31, 2026
Fidelity Extended Market Index Fund598,0100.47%$19.58M0.05%May 31, 2026
Schwab U.S. Small-Cap ETF555,6870.44%$18.19M0.08%May 31, 2026
Select Health Care Portfolio540,0000.42%$17.68M0.31%May 31, 2026
Fidelity Stock Selector Small Cap Fund537,4000.42%$17.06M0.23%Jul 31, 2026
iShares Russell Mid-Cap ETF467,1940.37%$18.23M0.03%Jun 30, 2026
Fidelity Advisor Biotechnology Fund450,1870.35%$14.29M0.65%Jul 31, 2026
Vanguard Explorer Fund444,1250.35%$14.10M0.06%Jul 31, 2026
Fidelity Mid Cap Index Fund428,6480.34%$13.61M0.03%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Brian LianPresident & CEO, Director2,572,4412.02%Jul 29, 2026
Greg ZanteChief Financial Officer212,2040.17%Jul 29, 2026
Marianna ManciniChief Operating Officer422,7600.33%Jul 29, 2026
Hubert C. ChenChief Medical Officer––Jun 3, 2026
Neil William AubuchonChief Commercial Officer4,4750.00%Mar 10, 2026
Dorothy Elizabeth Kelly-GemmellDirector6,3330.00%Aug 7, 2026
Lawson MacartneyDirector51,1150.04%Jan 5, 2026
Matthew W. FoehrDirector132,0360.10%Jan 5, 2026
Sarah Kathryn RouanDirector4,3900.00%Jan 5, 2026
Charles A. Rowland JrDirector33,1500.03%Jan 5, 2026
J. Matthew SingletonDirector12,6500.01%Jan 5, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Dorothy Elizabeth Kelly-Gemmell
Director
Aug 1, 2026Award+6,333––6,333
Brian Lian
President & CEO, Director
Jul 29, 2026Sale−148,517$33.32$4.95M2,572,441
Marianna Mancini
Chief Operating Officer
Jul 29, 2026Sale−18,217$33.47$609.72K422,760
Greg Zante
Chief Financial Officer
Jul 29, 2026Sale−21,217$33.47$710.13K212,204
Brian Lian
President & CEO, Director
Jul 28, 2026Award+221,667––2,720,958
Marianna Mancini
Chief Operating Officer
Jul 28, 2026Award+31,667––440,977
Greg Zante
Chief Financial Officer
Jul 28, 2026Award+31,667––233,421
Neil William Aubuchon
Chief Commercial Officer
Mar 10, 2026Buy+4,475$33.50$149.91K4,475
Greg Zante
Chief Financial Officer
Jan 5, 2026Sale−1,500$32.09$48.14K189,891
Greg Zante
Chief Financial Officer
Jan 5, 2026Sale−10,300$34.24$352.67K191,371
Greg Zante
Chief Financial Officer
Jan 5, 2026Sale−13,900$33.38$463.98K201,671
Greg Zante
Chief Financial Officer
Jan 5, 2026Sale−31,961$32.30$1.03M215,571
Marianna Mancini
Chief Operating Officer
Jan 5, 2026Sale−1,600$35.07$56.11K409,190
Marianna Mancini
Chief Operating Officer
Jan 5, 2026Sale−10,500$34.22$359.31K410,790
Marianna Mancini
Chief Operating Officer
Jan 5, 2026Sale−13,600$33.37$453.83K421,290
Marianna Mancini
Chief Operating Officer
Jan 5, 2026Sale−31,961$32.29$1.03M434,890
Brian Lian
President & CEO, Director
Jan 5, 2026Sale−132,454$32.29$4.28M2,600,246
Brian Lian
President & CEO, Director
Jan 5, 2026Sale−41,276$34.22$1.41M2,505,691
Brian Lian
President & CEO, Director
Jan 5, 2026Sale−53,279$33.38$1.78M2,546,967
Brian Lian
President & CEO, Director
Jan 5, 2026Sale−6,400$35.07$224.45K2,499,291
Sarah Kathryn Rouan
Director
Jan 2, 2026Award+3,150––4,390
J. Matthew Singleton
Director
Jan 2, 2026Award+3,150––12,650
Lawson Macartney
Director
Jan 2, 2026Award+3,150––51,115
Charles A. Rowland Jr
Director
Jan 2, 2026Award+3,150––33,150
Greg Zante
Chief Financial Officer
Jan 2, 2026Award+32,049––247,532
Greg Zante
Chief Financial Officer
Jan 2, 2026Award+41,000––215,483
Marianna Mancini
Chief Operating Officer
Jan 2, 2026Award+32,049––466,851
Marianna Mancini
Chief Operating Officer
Jan 2, 2026Award+41,000––434,802
Brian Lian
President & CEO, Director
Jan 2, 2026Award+78,400––2,508,620
Brian Lian
President & CEO, Director
Jan 2, 2026Award+224,080––2,732,700
Matthew W. Foehr
Director
Jan 2, 2026Sale−16,000$35.11$561.76K132,036
Matthew W. Foehr
Director
Jan 2, 2026Option exercise+16,000$3.33$53.28K148,036
Matthew W. Foehr
Director
Jan 2, 2026Award+3,150––135,186
Marianna Mancini
Chief Operating Officer
Oct 28, 2025Sale−6,185$35.00$216.48K382,467
Brian Lian
President & CEO, Director
Oct 28, 2025Sale−38,989$35.01$1.37M2,419,109
Greg Zante
Chief Financial Officer
Oct 28, 2025Sale−6,185$35.00$216.48K173,592
Marianna Mancini
Chief Operating Officer
Oct 27, 2025Award+11,117––388,652
Brian Lian
President & CEO, Director
Oct 27, 2025Award+70,084––2,458,098
Greg Zante
Chief Financial Officer
Oct 27, 2025Award+11,117––179,777
Charles A. Rowland Jr
Director
Oct 27, 2025Award+16,000$4.48$71.68K46,000
Charles A. Rowland Jr
Director
Oct 27, 2025Award+22,000$5.80$127.60K68,000
Charles A. Rowland Jr
Director
Oct 27, 2025Award+22,000$4.88$107.36K90,000
Charles A. Rowland Jr
Director
Oct 27, 2025Sale−60,000$35.57$2.13M30,000
Brian Lian
President & CEO, Director
Jul 3, 2025Sale−26,889$27.80$747.51K2,388,014
Marianna Mancini
Chief Operating Officer
Jul 3, 2025Sale−4,266$27.77$118.47K377,535
Greg Zante
Chief Financial Officer
Jul 3, 2025Sale−4,266$27.76$118.42K168,660
Brian Lian
President & CEO, Director
Jul 2, 2025Award+48,333––2,414,903
Marianna Mancini
Chief Operating Officer
Jul 2, 2025Award+7,667––381,801
Greg Zante
Chief Financial Officer
Jul 2, 2025Award+7,667––172,926
Matthew W. Foehr
Director
Apr 11, 2025Option exercise+20,786$8.00$166.29K132,036
Sarah Kathryn Rouan
Director
Mar 31, 2025Buy+1,240$24.15$29.95K1,240
Sarah Kathryn Rouan
Director
Mar 31, 2025Buy+1,240$24.15$29.95K1,240
Brian Lian
President & CEO, Director
Jan 6, 2025Sale−175,490$42.68$7.49M2,385,570
Brian Lian
President & CEO, Director
Jan 6, 2025Sale−19,000$43.32$823.08K2,366,570
Greg Zante
Chief Financial Officer
Jan 6, 2025Sale−45,609$42.69$1.95M169,959
Greg Zante
Chief Financial Officer
Jan 6, 2025Sale−4,700$43.32$203.60K165,259
Marianna Mancini
Chief Operating Officer
Jan 6, 2025Sale−5,100$43.32$220.93K374,134
Marianna Mancini
Chief Operating Officer
Jan 6, 2025Sale−49,115$42.69$2.10M379,234
Brian Lian
President & CEO, Director
Jan 3, 2025Award+163,333––2,561,060
Brian Lian
President & CEO, Director
Jan 3, 2025Award+92,800––2,397,727

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
19.48%
24M shares short
Days to cover
5.4
At 5M shares a day
Change since last report
-5.4%
From 26M shares
Short volume, 20 days
44.9%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Viking Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 144,254 shares on Sep 28, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Greg Zante
Officer
Jul 29, 202621,217$710.14KJul 29, 2026Performance Stock Units
Marianna Mancini
Officer
Jul 29, 202618,217$609.64KJul 29, 2026Performance Stock Units
Brian Lian
Officer
Jul 29, 2026148,517$4.95MJul 29, 2026Performance Stock Units
Brian Lian
Officer
Jan 5, 2026233,409$7.69MJan 5, 2026Performance Stock Units
Greg Zante
Officer
Jan 5, 202657,661$1.90MJan 5, 2026Performance Stock Units
Marianna Mancini
Officer
Jan 5, 202657,661$1.90MJan 5, 2026Restricted stock vesting under a registered plan
Matthew W. Foehr
Director
Jan 2, 202616,000$561.69KJan 2, 2026Exercise of options under a registered plan
Greg Zante
Officer
Oct 28, 20256,185$216.53KOct 28, 2025Performance Stock Units
Marianna Mancini
Officer
Oct 28, 20256,185$216.49KOct 28, 2025Performance Stock Units
Brian Lian
Officer
Oct 28, 202538,989$1.36MOct 28, 2025Performance Stock Units
Charles A. Rowland Jr
Director
Oct 27, 202560,000$2.13MOct 27, 2025Exercise of options under a registered plan
Brian Lian
Officer
Jul 3, 202526,889$747.63KJul 3, 2025Restricted stock vesting under a registered plan
Marianna Mancini
Officer
Jul 3, 20254,266$118.47KJul 3, 2025Restricted stock vesting under a registered plan
Greg Zante
Officer
Jul 3, 20254,266$118.43KJul 3, 2025Restricted stock vesting under a registered plan
Marianna Mancini
Officer
Jan 6, 202554,215$2.32MJan 6, 2025Restricted stock vesting under a registered plan

See a number that looks wrong?